Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01025934 |
|
Recruitment Status :
Completed
First Posted : December 4, 2009
Last Update Posted : December 4, 2009
|
Sponsor:
University of Campania "Luigi Vanvitelli"
Collaborator:
Napoli CTO Hospital
Information provided by:
University of Campania "Luigi Vanvitelli"
| Tracking Information | |||
|---|---|---|---|
| First Submitted Date ICMJE | December 3, 2009 | ||
| First Posted Date ICMJE | December 4, 2009 | ||
| Last Update Posted Date | December 4, 2009 | ||
| Study Start Date ICMJE | Not Provided | ||
| Primary Completion Date | Not Provided | ||
| Current Primary Outcome Measures ICMJE | Not Provided | ||
| Original Primary Outcome Measures ICMJE | Not Provided | ||
| Change History | No Changes Posted | ||
| Current Secondary Outcome Measures ICMJE | Not Provided | ||
| Original Secondary Outcome Measures ICMJE | Not Provided | ||
| Current Other Pre-specified Outcome Measures | Not Provided | ||
| Original Other Pre-specified Outcome Measures | Not Provided | ||
| Descriptive Information | |||
| Brief Title ICMJE | Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy | ||
| Official Title ICMJE | Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy | ||
| Brief Summary | The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy. | ||
| Detailed Description | Not Provided | ||
| Study Type ICMJE | Interventional | ||
| Study Phase ICMJE | Phase 4 | ||
| Study Design ICMJE | Primary Purpose: Treatment | ||
| Condition ICMJE | Proliferative Diabetic Retinopathy | ||
| Intervention ICMJE |
|
||
| Study Arms ICMJE |
|
||
| Publications * | di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):785-91. doi: 10.1007/s00417-010-1303-3. Epub 2010 Feb 5. | ||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||
| Recruitment Information | |||
| Recruitment Status ICMJE | Completed | ||
| Enrollment ICMJE | Not Provided | ||
| Original Enrollment ICMJE | Not Provided | ||
| Study Completion Date ICMJE | Not Provided | ||
| Primary Completion Date | Not Provided | ||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||
| Sex/Gender ICMJE |
|
||
| Ages ICMJE | Child, Adult, Older Adult | ||
| Accepts Healthy Volunteers ICMJE | Yes | ||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||
| Listed Location Countries ICMJE | Not Provided | ||
| Removed Location Countries | |||
| Administrative Information | |||
| NCT Number ICMJE | NCT01025934 | ||
| Other Study ID Numbers ICMJE | IVBDRNA | ||
| Has Data Monitoring Committee | No | ||
| U.S. FDA-regulated Product | Not Provided | ||
| IPD Sharing Statement ICMJE | Not Provided | ||
| Responsible Party | Not Provided | ||
| Study Sponsor ICMJE | University of Campania "Luigi Vanvitelli" | ||
| Collaborators ICMJE | Napoli CTO Hospital | ||
| Investigators ICMJE | Not Provided | ||
| PRS Account | University of Campania "Luigi Vanvitelli" | ||
| Verification Date | December 2009 | ||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||